| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Dairy Farmers of Canada
Address reprint requests to: Helen B. MacDonald, Dairy Farmers of Canada, 1801 McGili College Avenue, Suite 1000, Montreal, Quebec, H3A 2N4, CANADA.
Conjugated linoleic acid (CLA), a derivative of a fatty acid linoleic acid (LA), has been reported to decrease tumorigenesis in animals. CLA is unique because unlike most antioxidants which are components of plant products, it is present in food from animal sources such as dairy foods and meats. CLA concentrations in dairy products typically range from 2.9 to 8.92 mg/g fat of which the 9-cis, 11-trans isomer makes up to 73% to 93% of the total CLA. Low concentrations of CLA are found in human blood and tissues. In vitro results suggest that CLA is cytotoxic to MCF-7 cells and it inhibits the proliferation of human malignant melanoma and colorectal cancer cells. In animal studies, CLA has inhibited the development of mouse epidermal tumors, mouse forestomach cancer and rat mammary cancer. Hamsters fed CLA collectively had significantly reduced levels of plasma total cholesterol, non-high-density lipoprotein cholesterol, (combined very-low and low-density lipoprotein) and triglycerides with no effect on high-density lipoprotein cholesterol, as compared to controls. Dietary CLA modulated certain aspects of the immune defense but had no obvious effect on the growth of an established, aggressive mammary tumor in mice. It is now thought that CLA itself may not have anti-oxidant capabilities but may produce substances which protect cells from the detrimental effects of peroxides.
There is, however, insufficient evidence from human epidemiological data, and very few of the animal studies have shown a dose-response relationship with the quantity of CLA feed and the extent of tumor growth. Further research with tumor models is needed to test the efficacy and utility of CLA in cancer and other disease prevention and form the basis of evaluating its effect in humans by observational studies and clinical trials.
Key words: conjugated linoleic acid, CLA, cancer, heart disease, antioxidant, fatty acids
This article has been cited by other articles:
|
|
 |
|
  E. F. Murphy, G. J. Hooiveld, M. Muller, R. A. Calogero, and K. D. Cashman Conjugated Linoleic Acid Alters Global Gene Expression in Human Intestinal-Like Caco-2 Cells in an Isomer-Specific Manner J. Nutr., November 1, 2007; 137(11): 2359 - 2365. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Platt, L. G. Rao, and A. El-Sohemy Isomer-Specific Effects of Conjugated Linoleic Acid on Mineralized Bone Nodule Formation from Human Osteoblast-LikeCells Experimental Biology and Medicine, February 1, 2007; 232(2): 246 - 252. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Arbones-Mainar, M. A. Navarro, S. Acin, M. A. Guzman, C. Arnal, J. C. Surra, R. Carnicer, H. M. Roche, and J. Osada Trans-10, cis-12- and cis-9, trans-11-Conjugated Linoleic Acid Isomers Selectively Modify HDL-Apolipoprotein Composition in Apolipoprotein E Knockout Mice J. Nutr., February 1, 2006; 136(2): 353 - 359. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. E. Loscher, E. Draper, O. Leavy, D. Kelleher, K. H. G. Mills, and H. M. Roche Conjugated Linoleic Acid Suppresses NF-{kappa}B Activation and IL-12 Production in Dendritic Cells through ERK-Mediated IL-10 Induction J. Immunol., October 15, 2005; 175(8): 4990 - 4998. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. A. Reh, E. A. Maga, N. M. B. Collette, A. Moyer, J. S. Conrad-Brink, S. J. Taylor, E. J. DePeters, S. Oppenheim, J. D. Rowe, R. H. BonDurant, et al. Hot Topic: Using a Stearoyl-CoA Desaturase Transgene to Alter Milk Fatty Acid Composition J Dairy Sci, October 1, 2004; 87(10): 3510 - 3514. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. J. Gibb, F. N. Owens, P. S. Mir, Z. Mir, M. Ivan, and T. A. McAllister Value of sunflower seed in finishing diets of feedlot cattle J Anim Sci, September 1, 2004; 82(9): 2679 - 2692. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Wang and P. J. Jones Dietary conjugated linoleic acid and body composition Am. J. Clinical Nutrition, June 1, 2004; 79(6): 1153S - 1158S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. G Taylor and P. Zahradka Dietary conjugated linoleic acid and insulin sensitivity and resistance in rodent models Am. J. Clinical Nutrition, June 1, 2004; 79(6): 1164S - 1168S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. S McLeod, A. M LeBlanc, M. A Langille, P. L Mitchell, and D. L Currie Conjugated linoleic acids, atherosclerosis, and hepatic very-low-density lipoprotein metabolism Am. J. Clinical Nutrition, June 1, 2004; 79(6): 1169S - 1174S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. O. McCarthy Rethinking Nutritional Support for Persons with Cancer Cachexia Biol Res Nurs, July 1, 2003; 5(1): 3 - 17. [Abstract] [PDF]
|
|
|
|
 |
|
 U. Riserus, S. Basu, S. Jovinge, G. N. Fredrikson, J. Arnlov, and B. Vessby Supplementation With Conjugated Linoleic Acid Causes Isomer-Dependent Oxidative Stress and Elevated C-Reactive Protein: A Potential Link to Fatty Acid-Induced Insulin Resistance Circulation, October 8, 2002; 106(15): 1925 - 1929. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. E Voorrips, H. A. Brants, A. F. Kardinaal, G. J Hiddink, P. A van den Brandt, and R A. Goldbohm Intake of conjugated linoleic acid, fat, and other fatty acids in relation to postmenopausal breast cancer: the Netherlands Cohort Study on Diet and Cancer Am. J. Clinical Nutrition, October 1, 2002; 76(4): 873 - 882. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. E. Mosley, G. L. Powell, M. B. Riley, and T. C. Jenkins Microbial biohydrogenation of oleic acid to trans isomers in vitro J. Lipid Res., February 1, 2002; 43(2): 290 - 296. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. D. Miller, J. K. Jarvis, and L. D. McBean The Importance of Meeting Calcium Needs with Foods J. Am. Coll. Nutr., April 1, 2001; 20(2): 168S - 185. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
